Neonatal thyroid disorders

A L Ogilvy-Stuart

Hypothyroxinaemia, which is common in the preterm infant, and thyrotoxicosis, which is rare, are important neonatal thyroid disorders. Their causes and treatment are discussed.

Thyroid hormones are important for energy metabolism, the metabolism of nutrients and inorganic ions, thermogenesis, and for stimulation of growth and development of various tissues at critical periods including the central nervous system and skeleton. A number of tissue and cell functions are modified by varying patterns of genomic activation and protein and receptor synthesis, which accounts for the many variable actions. Thyroid hormones potentiate the actions of catecholamines (the effects of which are prominent in the hyperthyroid state), and their effect on somatic and skeletal growth are in part mediated by stimulation of the synthesis and action of growth hormone and insulin-like growth factor.

In this review, I will discuss the ontogeny of thyroid function, thyroid function in preterm infants, and the use of thyroid hormones in these babies. I will review neonatal thyrotoxicosis and, finally, give suggestions for the investigation of babies born to mothers with thyroid disease.

DEVELOPMENT OF THYROID FUNCTION

During fetal life, the thyroid gland develops with production of thyroxine (T4) and triiodothyronine (T3) and secretion into the serum from about 12 weeks gestation, the levels of which increase to term. Throughout gestation, maternal T4 crosses the placenta in limited amounts, but in the first trimester, this plays a critical role in central nervous system development, as exemplified by the fetal neurological impairment seen in fetomaternal Pit-1 deficiency and severe iodine deficiency. In both situations there is severe maternal and fetal hypothyroidism. In areas of endemic iodine deficiency, iodine supplementation to women before pregnancy or up to the end of the second trimester protects the fetal brain from the effects of iodine deficiency whereas third trimester or neonatal supplementation does not improve neurological outcome.

From the second trimester, the continued transfer of T4 from mother to fetus remains important for those babies with primary thyroid abnormalities, as despite cord blood levels only reaching about 40% of normal in those with a total inability to synthesise T4, neurological development is near normal if replacement is started promptly. From mid-gestation, hypothalamic expression of thyrotrophin releasing hormone (TRH), pituitary production of thyroid stimulating hormone (TSH), and thyroidal production of T4 rise steadily until 36 weeks gestation. Even when the fetal thyroid gland becomes autonomous, normal thyroid function in the mother may be important for normal neurological development.

The bioactivity of thyroid hormone is regulated by enzymic deiodination in peripheral tissues. T4 is converted by outer ring deiodination into T3, which has three to four times the metabolic potency of T4. Both T4 and T3 are inactivated by inner ring deiodination to reverse T3 (rT3) and 3,3′-diodothyronine respectively. Three iodothyronines are involved in this process. Type I deiodinase (D1) has both inner and outer ring deiodination activity. It is located in the liver, kidney, and the thyroid and is important for T3 production. Type II deiodinase (D2) catalyses only outer ring deiodination and is found in the brain, pituitary, and brown adipose tissue. It is important for local T3 production within these tissues. Type III deiodinase (D3) has only inner ring activity and is present in brain, skin, and intestine.

T3 and T4 are also inactivated to sulphated analogues by sulphotransferase in fetal liver. Sulphated iodothyronines are major thyroid hormone metabolites in the fetus, and sulphate conjugation of the iodothyronines accelerates deiodination.

In the fetus, levels of T3 are low, and increase only at the end of gestation. In contrast, T4 levels are high, only decreasing in late gestation and into the neonatal period. Hence endogenous thermogenesis is minimised and anabolism is promoted. High D3 activity in the placenta (converting a large proportion of T4 and T3 into rT3 and 3,3′-diodothyronine during placental transfer), and in both fetal liver and the liver of preterm babies contribute to the high rT3 levels. Both D1 and D2 are present from the third trimester—the increase in D1 activity mirrored by a rise in T3 from 30 weeks gestation. Fetal tissues that are dependent on T3 (particularly the brain) rely on local T4 into T3 conversion via D2.

THYROID FUNCTION IN THE PRETERM BABY

In the preterm baby, and fetus of similar gestation, the thyroid axis is immature, with reduced hypothalamic TRH production and secretion, an immature response of the thyroid gland to TSH, an inefficient capacity of the follicular cell

Abbreviations: T4, thyroxine; T3, triiodothyronine; TRH, thyrotrophin releasing hormone; TSH, thyroid stimulating hormone; TSI, thyroid stimulating immunoglobulin; PTU, propylthiouracil
of the thyroid to organise iodine, and a low capacity to convert 
T4 into active T3. Hence, when a baby is born preterm, the level 
of T4 is lower than that of term babies and correlates with 
gestational age and birth weight.15 Levels of TSH and T3 are 
normal to low, free T4 concentrations are also low, and 
thyroglobulin levels are high (reflecting increased thyroid gland 
production of poorly iodinated thyroid hormone precursor). Responses of TSH and T4 to TRH are normal, 
reflecting that the site of immaturity is the hypothalamus. In 
addition, hypothyroxaemia is in part secondary to reduced 
levels of thyroid binding globulin. These data would suggest 
that the hypothyroxaemia of prematurity is physiological.

Normally at delivery at term, with the fall in ambient tem-
perature, there is a surge in TSH to about 80 mU/ml within 
about 30 minutes. This stimulates the thyroid gland to release 
T4 and T3, which rise to well above normal levels. In term 
babies, the total and free T4 levels fall over the next four to six 
weeks, but are still higher than in older children and adults at 
six months. T3 levels gradually reach infancy levels between 2 
and 12 weeks of age.

In the preterm infant, there is a similar TSH, T4, and T3 
surge, but the magnitude is attenuated. In babies born at more 
than 30 weeks gestation, T4 and free T4 levels increase over the 
next six to eight weeks to levels comparable to those of babies 
born at term.14,15 However, in the preterm baby born at less 
than 30 weeks gestation and with very low birth weight (< 1500 g), the TSH and T4 surges are limited and there is 
often a fall in T4 in the first one to two weeks after birth, and 
transient hypothyroxaemia is common. The more pre-
term the baby the more pronounced is this hypothyroxaemia. 
Although there is an increase in the incidence of transient 
primary hypothyroidism in these babies (when the 
TSH level is also raised),16 in the majority, the hypothyroxaemia 
is associated with a normal TSH level.17 The severity of the 
neonatal illness is also reflected in the T4 levels, with infants 
who require ventilatory assistance for respiratory distress 
syndrome having the lower T4 levels,17 possibly suggesting 
non-thyroidal illness (sick euthyroid syndrome), which may 
be an adaptive response to illness resulting in a depressed 
metabolic rate.

The reason for this hypothyroxaemia is multifactorial, 
including the loss of the maternal T4 contribution, immaturity 
of the hypothalamic-pituitary axis, the responsiveness of the 
thyroid gland to TSH, and immaturity of peripheral tissue 
deiodination. Iodine balance is negative in the first few weeks 
after birth in these very low birthweight babies, suggesting an 
ability to augment thyroidal iodine uptake and increase T4 
secretion.18 These changes are further compounded by iodine 
deficiency in areas of the world with low environmental 
iodine, and by the use of iodine-containing antiseptics, drugs, 
and contrast agents.19 The relatively low T3 levels are not 
increased by T4 administration, probably because of low D1 
levels in the liver—most of the circulating T3 coming from 
thyroidal production.20

DOES THIS HYPOTHYROXAEMIA MATTER?

In preterm infants, almost all reports document an association 
between adverse outcome and hypothyroxaemia. Severe 
hypothyroxaemia, as measured on blood spots in newborn 
screening programmes that utilise T4 (rather than TSH, which 
is used in the United Kingdom), has been associated with an 
increase in perinatal mortality and morbidity, with prolonged 
oxigen supplementation, mechanical ventilation, and hospital 
stay,21 an increased incidence of intraventricular haemorrhage,22 
and a greater risk of echolucencies in cerebral white matter 
on ultrasonography.23 In the survivors, an increased risk of neurodevelopmental problems, reduced intelligence quotient (IQ),24–26 and disabling cerebral palsy 27 has been reported, even when corrected for potential 
confounders including gestation, fetal growth, and illness 
severity. A British cohort in which T3 was measured twice in 
the first week and weekly thereafter in babies of less than 1850 g has shown an association between a T3 level less than 0.3 nmol/l and a reduction on the Bayley mental developmen-
tal index score, and the Bayley psychomotor index score of 8.3 
points and 7.4 points respectively at 18 months, even with 
adjustment for confounding variables known to affect 
outcome.28 When reassessed between 7.5 and 8 years, overall 
IQ was 6.6 points lower in those whose lowest T3 had been 
< 0.3 nmol/l.29

SHOULD PRETERM BABIES BE SUPPLEMENTED WITH 
THYROID HORMONES?

It is unclear whether this association between low T3 or low T4 
and short term morbidity, mortality, and long term disability is 
causal or merely a reflection of illness severity in the most 
premature babies. However, this has resulted in a number of 
studies of thyroid hormone supplementation in an attempt to 
reduce these problems. The numbers in each study are small 
and the use of different doses at different times and different 
thyroid hormones (T4 or T3) precludes a meta-analysis. Of the 
eight published studies, four were randomised or quasi-
randomised controlled trials and have been summarised in a 
Cochrane review.30 In the first of these studies, Chowdrey et al31 
compared treatment with thyroxine with treatment with 
placebo in babies of 25–28 weeks gestation with hypothyroxi-
aemia (T4 < 4 µg/dl and TSH < 20 IU/l on two occasions). There was no effect of thyroid supplementation on linear 
growth, weight gain, head circumference at 10 months, or 
psychomotor development at 12 and 24 months, and no 
difference in mortality. Apart from small numbers (11 treated 
v 12 placebo), it should be noted that T4 treatment was not 
started until T4 levels were at their lowest (2 weeks), and T4 
treatment did not increase T4 levels. In addition, there was 
evidence of long term psychomotor disability in the T4 treated 
patients with developmental scores of approximately 85.

Amato et al32 studied babies of less than 32 weeks gestation, 
requiring more than 40% supplemental oxygen. Treatment 
with T4 (50 µg/kg/day in two doses intravenously), started on 
the first day of life for two days, was compared with no treat-
ment. Mortality (38%) was the same in both groups, although 
there was a lowered Fio2 in the first 72 hours and there was no 
long term effect on any other respiratory outcome. Neuro-
development was not assessed.

Vanhole et al33 undertook a double blind, placebo controlled 
study of T4 treatment (20 µg/kg/day from day 1 for two weeks) 
for babies born at 25–30 weeks gestation. There was no effect 
on mortality, respiratory complications including chronic lung 
disease, intraventricular haemorrhage, retinopathy of prematu-
rety, or growth. There was no difference in the Bayley men-
tal development index or Bayley psychomotor developmental 
index at 7 months corrected age.

Van Wassenaeer et al34 also conducted a double blind, placebo 
controlled study of T4 (8 µg/kg/day for six weeks) in babies 
of 25–29 weeks gestation. Whereas the T4 levels in the placebo 
group fell by day 7, they rose in the treatment group in the first 
3 days with no nadir at 7 days. Although T4 levels remained 
raised, they were lowest in babies of 25 and 26 weeks 
gestation. Both thyrotrophin and T3 levels were suppressed 
during T3 treatment. On discontinuation of T4 at 6 weeks of 
age, T4 levels fell and were below cord blood levels at 56 days 
in babies born at 25 and 26 weeks gestation. There was no sig-
ificant difference in mortality, severity of respiratory disease, 
intraventricular haemorrhage, or periventricular leucomala-
cia. There was no significant difference in Bayley mental 
development index or psychomotor developmental index per-
formed at 6, 12, and 24 months of age. However, in a postcri-
ori subgroup analysis by gestational age at 24 months, there 
was a significant difference in the Bayley mental development 
index (18 points higher) in the T4 treated group born at 25–26

www.archdischild.com

Arch Dis Child Fetal Neonatal Ed: first published as 10.1136/fn.87.3.F165 on 1 November 2002. Downloaded from http://fn.bmj.com/ on May 20, 2022 by guest. Protected by copyright.
weeks gestation compared with the placebo group, but a significantly lower mental development index (10 points) in T4 treated infants of 27–29 weeks gestation.

Although there are obvious pitfalls in posteriori analysis, this study does pose a number of questions that require clarification. The data suggest that the nadir in thyroid hormones seen at 7 days in the extremely preterm baby may be detrimental to brain development but has little effect on respiratory function or growth. There was no assessment of thyroid function before T4 was started, so it is possible that some babies had underlying thyroid or hypothyramic-pituitary dysfunction.

Also of concern is the suggestion that supplemental T4 may be detrimental to babies born after 26 weeks gestation. These data are supported by an ACTOBAT (Australian collaborative trial of antenatal thyrotropin-releasing hormone) trial in which 200 µg TRH was administered in addition to corticosteroids to women at risk of preterm delivery to ascertain whether in those with normal thyrotropin levels (and no abnormalities of the hypothalamic-pituitary axis) this is an association (usually in the sickest infants) or the cause. The data to date do not support supplementation with thyroid hormones in these babies, and indeed it may be detrimental to long term neurological outcome. The possible advantage to those babies born at 25 and 26 weeks gestation requires further clarification before recommendation of thyroid hormone supplementation. These conclusions are supported by a recent American review.5

**NEONATAL THYROTOXICOSIS**

Although rare, this condition is associated with a high mortality and needs to be anticipated so that, if necessary, treatment can be instigated promptly.

The cause of hyperthyroidism in the newborn is usually transplacental passage of thyroid stimulating immunoglobulins (TSIs) from mothers with Graves’ disease, or, more rarely, Hashimoto’s thyroiditis.6 TSIs may continue to be produced even after ablation of the thyroid gland with surgery or radioiodine. Neonatal thyrotoxicosis secondary to TSIs is a transient disorder, limited by the clearance of maternal antibody from the baby’s circulation. In contrast, a rarer form of persistent hyperthyroidism, which is usually dominantly inherited, can occur in the absence of maternal autoimmunity because of activating mutations in the TSH receptor6–10 and activating mutations of the stimulatory G protein in McCune-Albright syndrome.6–10 Activating mutations of the TSH receptor should be suspected if there are more than two generations affected with thyrotoxicosis, or there are other first degree relatives with thyrotoxicosis, as the condition may be easily missed.

Neonatal hyperthyroidism is rare. The prevalence of Graves’ disease in pregnant women is approximately 0.2%.6,44 Although it is usually stated that only 1–1.5% of their offspring will have overt hyperthyroidism, this figure may be much higher: 5%,44 8%,6 10%,45 and 12.5%46 have been quoted. Thus there will be one case of overt neonatal hyperthyroidism for every 4000–50 000 deliveries, with a further 3% of babies with Graves’ disease having biochemical thyrotoxicosis in the absence of symptoms.48 The incidence of hyperthyroidism in babies of mothers who require treatment with antithyroid drugs to term may be as high as 22%.47 The mortality has been reported to be 12–20%,44 61 usually from heart failure, but other complications include tracheal compression, infections, and thrombocytopenia.

**CLINICAL FEATURES**

Fetal outcome is related to the control of maternal thyrotoxicosis, with complications being considerably increased in mothers who remain hyperthyroid in the second half of pregnancy.49 The hyperthyroid fetus is often growth retarded, both from a direct effect of hyperthyroidism and associated pre-eclampsia.50 Tachycardia is common and often used to diagnose fetal thyrotoxicosis. Non-immune hydrops has been described, presumably secondary to cardiac failure.51 Goitre may be apparent on ultrasound scanning.

There is an increased incidence of intrauterine death which has been reported to occur in 5–7% of offspring of mothers receiving medical or surgical treatment for thyrotoxicosis and in 24% of offspring of untreated, hyperthyroid mothers.52 Premature delivery occurs in 4–11% of mothers treated for thyrotoxicosis during pregnancy and in 53% of mothers who remain untreated.53

In the neonate, symptoms and signs of thyrotoxicosis may be apparent at birth or may be delayed for several days, because of either the effect of maternal antithyroid drugs or the effect of coexistent blocking antibodies,54 55 but are usually apparent by 10 days of life.56 However, overt thyrotoxicosis has been reported to occur as late as 45 days after birth.57 Levels of TSH binding inhibitor immunoglobulin and TSH immunoglobulin levels from mothers during the third trimester and in the infant in the neonatal period correlate well with the development of neonatal hyperthyroidism.46–50

Most infants have a goitre. Central nervous system signs include irritability, jitteriness, and restlessness. Eye signs such as periorbital oedema, lid retraction, and exophthalmos may be present even in the absence of maternal eye signs. Exophthalmos can occur even in thyrotoxicosis secondary to causes other than maternal Graves’ disease.57 Cardiovascular signs include tachycardia and arrhythmias, but may progress to cardiac failure. Systemic and pulmonary hypertension may be present. Signs of hypermetabolism include voracious appetite, weight loss, diarrhoea, sweating, and flushing. Other signs include persisting acrocyanosis, hepatosplenomegaly, lymphadenopathy, thyric enlargement, bruising and petechiae secondary to thrombocytopenia, and hyperviscosity. Advanced bone age, craniosynostosis, and microcephaly may be evident in both the fetus and newborn.

The duration of neonatal thyrotoxicosis secondary to maternal Graves’ disease is determined by the persistence of transplacentally acquired maternal TSIs and usually remits after 8–20 weeks.58 Virtually all infants are euthyroid by 48 weeks postnatal age.59 Rarely the thyrotoxicosis persists, possibly because of endogenous TSH production, and these children may require ablative thyroid treatment.60 Patients with apparent persistent neonatal Graves’ disease often have an autosomal dominant pattern of inheritance, which is also observed in families with activating mutations in the TSH receptor.61 Some families thought to have persistent neonatal Graves’ disease may therefore have TSH receptor mutations.

Table 1  Babies at high risk of neonatal thyrotoxicosis

<table>
<thead>
<tr>
<th>Mother</th>
<th>Baby</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raised thyroid binding immunoglobulin levels in pregnancy</td>
<td>Evidence of fetal thyrotoxicosis</td>
</tr>
<tr>
<td>Thyroid binding immunoglobulin level not assessed</td>
<td></td>
</tr>
<tr>
<td>Clinical thyrotoxicosis in third trimester</td>
<td></td>
</tr>
<tr>
<td>Thionamide required in third trimester</td>
<td></td>
</tr>
<tr>
<td>Family history of TSH receptor mutation</td>
<td></td>
</tr>
</tbody>
</table>
Transient neonatal hypothyroidism may occur in babies of mothers with a current or past history of Graves’ disease. This may be due to transplacental passage of thionamides, but apparent transient “athyrosis” has been documented secondarily to the blocking nature of some thiotriphen binding inhibitory immunoglobulins. Interestingly, some babies may develop transient hypothyroxinaemia, with a picture of central hypothyroidism. The mechanism for this may be suppression of the fetal (and then neonatal) thyroid axis by excessive T4 from either the thyrotropic mother or thyrotoxic baby (secondary to transplacental passage of TSI).

LONG TERM EFFECTS
Although there is a report of an increase in congenital anomalies in babies of mothers who were hyperthyroid at the time of embryogenesis, this has not been confirmed. There is generally no increase in congenital anomalies in babies of mothers receiving antithyroid drugs. Carbimazole is rapidly converted in the liver into methimazole, which is the preparation available in the United States. The latter has been linked to the development of cutis aplasia in the offspring of mothers treated with thionamides in pregnancy, although several large series studies have not confirmed this observation. Of greater concern is that the fetus of a mother on thionamides may be rendered hypothyroid; however, there is no evidence of greater concern, so I would recommend that all but the mildest biochemical hyperthyroidism should be treated. It is probable, however, that the effects on the developing brain and skeleton have been initiated in utero. Induced hypothyroidism secondary to treatment may be just as detrimental and needs to be closely monitored.

Medical treatment follows the same principals as treatment of older subjects. Thionamides (PTU and carbimazole) act by blocking the organification of iodine and the coupling of iodothyronine residues—that is, blocking thyroid hormone synthesis. In addition, PTU inhibits the peripheral deiodination of T4 to more active T3 and may therefore be the preferred drug.

The thyrotropic newborn may be treated with either 5–10 mg/kg/day PTU in three divided doses or 0.5–1.5 mg kg/day carbimazole as a single daily dose. As the drugs block the synthesis but not the release of thyroid hormones, a clinical response to thionamides may not occur until the thyroid hormone stored in the colloid is depleted. Therefore iodine solution, which suppresses thyroid hormone synthesis and has a prompt effect in inhibiting the release of thyroid hormones, may be used in conjunction with saturated KI (48 mg iodine per drop) may be given in a dose of 1 drop daily, or Lugol’s solution (5% KI; about 8 mg iodine/drop) may be given in a dose of 1 to 3 drops daily. By virtue of their iodine content inhibiting thyroid secretion and their ability to inhibit extrathyroidal conversion of T4 into T3, iopanoic acid and sodium iodate have also been used successfully in the treatment of neonatal thyrotoxicosis. The stated dose is 0.5 g every three days.

β-Blockers are effective in controlling symptoms caused by adrenergic stimulation. In addition, they inhibit deiodination of T4 to T3. Propranolol may be used in a dose of 0.27–0.75 mg/kg 8 hourly. However, it can cause serious hypoglycaemia, bradycardia, and hypotension, so babies require close monitoring. Specific treatment for cardiac failure may be required, for example with digoxin and diuretics.

Severely thyrotoxic babies may be treated with prednisolone, which suppresses deiodination of T4 to T3 and compensates for hypercatabolism of endogenous glucocorticoids induced by T3 and T4. The dose of prednisolone is 2 mg/kg/day.

Sedatives may also be helpful in managing irritability and restlessness.

Exchange transfusion has been used in an attempt to reduce TSI levels (or incidentally to treat haemolytic disease of the newborn), with some reduction in antibody levels but failing to prevent neonatal thyrotoxicosis. If a baby requires treatment for thyrotoxicosis, it should be reviewed approximately weekly until stable, then every one to two weeks, and drug doses reduced when possible. Treatment

www.archdischild.com
(1) Maternal hypothyroidism

This is usually secondary to Hashimoto’s thyroiditis and the mother may be producing thyroid inhibiting or rarely thyroid stimulating antibodies so the baby may develop transient hypothyroidism or, very rarely, hyperthyroidism. These babies should be reviewed at 10 days to 2 weeks and thyroid function taken (TSH and fT4).

If the maternal hypothyroidism is secondary to congenital aplasia or hypoplasia of the thyroid gland, there is only a slightly increased risk to the baby of hypothyroidism and Guthrie should suffice.

If the hypothyroidism is secondary to treatment (surgery or radioiodine) for Graves’ disease, the baby is at risk of neonatal thyrotoxicosis and will need to be managed as below.

(2) Maternal thyrotoxicosis

**Babies at risk for congenital hyperthyroidism**

(Maternal Graves’ disease, family history of activating mutations in TSH receptor)

Cord blood for fT4, TSH, TSI (if available) concentration + examination

- If high risk (table 1) repeat fT4, TSH + examination
  - Age 2–7 days:

- In all babies, repeat fT4, TSH and examination
  - Age 10–14 days

Results of thyroid function from any of the above:

- Normal
  - No treatment
- Hypothyroid
  - Repeat fT4 and TSH
  - Treat with thyroxine if confirmed
- Hyperthyroid
  - Consider treatment
  - PTU/carbamazole
  - +/- iodide
  - +/- propranolol

---

**Figure 1** Investigation of babies of mothers with thyroid disease. TSH, Thyroid stimulating hormone; fT4, free thyroxine; TSI, thyroid stimulating immunoglobulin; PTU, propylthiouracil.

---

Neonatal thyrotoxicosis is rare, but in babies born to mothers with Graves’ disease is usually required for four to eight weeks. In contrast, thyrotoxicosis secondary to activating mutations of the TSH receptor is persistent and may require ablative treatment usually with surgery. In view of the uncertain long term complications, neurodevelopmental follow up may be appropriate.

SUMMARY

In the preterm infant, hypothyroxinaemia is common. Although the degree of hypothyroxinaemia is associated with morbidity and mortality, it is unclear whether this is the cause or simply a reflection of illness severity. Supplementation with thyroid hormones is unlikely to influence tissue levels of T3, which are determined by specific deiodinase enzymes, and may even be detrimental.

Neonatal thyrotoxicosis is rare, but in babies born to mothers with a current or past history of Graves’ disease is more likely to occur if there are high levels of maternal TSI or thyrotoxicosis develops or requires treatment in pregnancy, or if the fetus is affected. Cord blood should be taken to assess thyroid function, and babies should be reviewed clinically and biochemically at 2 days (if the risk of thyrotoxicosis is high or unknown) and 1–2 weeks of postnatal age for evidence of thyrotoxicosis or hypothyroidism. Thyrotoxicosis should be treated with a thionamide, with or without iodide, or iodine-containing contrast medium. Propranolol and corticosteroids should be considered in severe cases. The general practitioner should be informed and the parents warned about potential signs of thyrotoxicosis.

REFERENCES

Role of sulfation in thyroid hormone metabolism. Thyroid 1997; 8(1):293–303.


Archimedes

In order to give the best care to patients and families, paediatricians need to integrate the highest quality scientific evidence with clinical expertise and the opinions of the family. Archimedes is a bimonthly section in Archives which seeks to assist practising clinicians by providing "evidence based" answers to common questions which are not at the forefront of research but are at the core of practice.

The format of Archimedes may be familiar. A description of the clinical setting is followed by a structured clinical question and a brief report of the search. The best evidence available to answer the question is provided as a summary table (which is electronically linked to more detailed appraisals). To pull the information together, a commentary follows. Finally, to make it all much more accessible, a box provides the clinical bottom line.

This month the following topics have been published which may be of interest to neonatologists:

- Are topical corticosteroids superior to systemic histamine antagonists in treatment of allergic seasonal rhinitis?
- Do behavioural treatments for sleep disorders in children with Down’s syndrome work?
- Inhaled steroids in the treatment of mild to moderate persistent asthma in children: once or twice daily administration?

Previous Archimedes questions can be found in the issues of Archives published in the Fetal and Neonatal edition months since September 2001. Readers wishing to submit their own questions—with best evidence answers—are encouraged to read the Instructions for Authors at http://www.archdischild.com.